BrandWikiReturn

Tibotec

Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002. The company is part of Johnson & Johnson Innovation Medicine business segment.

The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).[1]

History

In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels joined Tibotec. The company was acquired by Johnson & Johnson in April 2002,[2] and was renamed Janssen Therapeutics in June 2011.[3]

Tibotec provided funding for HIV treatment clinical trials at the Infectious Diseases Institute in Kampala, Uganda.[4][5]

Drugs

  • Darunavir (TMC114, tradename Prezista), a protease inhibitor
  • Etravirine (TMC125, tradename Intelence), a non-nucleoside reverse transcriptase inhibitor (NNRTI)
  • Bedaquiline (TMC207/R207910, tradename Sirturo), an diarylquinoline anti-tuberculosis drug[6]
  • Rilpivirine (TMC278, tradename Edurant), an NNRTI
  • Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.[7]
  • Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

See also

External links

References

  1. Rudi Pauwels, Koen Andries, Jan Desmyter, Dominique Schols, Michael J. Kukla, Henry J. Breslin, Alfons Raeymaeckers, Jozef Van Gelder. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives Nature, 1990^
  2. Johnson & Johnson to Acquire Tibotec-Virco Johnson & Johnson, 2002-03-22, retrieved 2023-05-16^
  3. Pamela Van Houten. Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies Johnson & Johnson, 2011-06-22, retrieved 2023-05-17^
  4. Sharon Schmickle. University of Minnesota doctors battle AIDS in Uganda MinnPost, 2008-11-13, retrieved 2023-05-16^
  5. Clinical Research at the Infectious Diseases Institute The Global Health Network, Infectious Diseases Institute, retrieved 2023-05-17^
  6. K. Andries, P Verhasselt, J Guillemont, H. W. Göhlmann, J. M. Neefs, H Winkler, J Van Gestel, P Timmerman. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis Science, 2005^
  7. Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2.^